Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ: ABOS · Real-Time Price · USD
3.140
+0.310 (10.95%)
At close: Feb 27, 2026, 4:00 PM EST
3.120
-0.020 (-0.64%)
After-hours: Feb 27, 2026, 7:52 PM EST
Acumen Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | - | - | - | - | - | 1.44 | |
| Revenue Growth (YoY) | - | - | - | - | - | -15.38% | |
| Cost of Revenue | 118.93 | 93.8 | 42.32 | 32.36 | 12.31 | 8 | |
| Gross Profit | -118.93 | -93.8 | -42.32 | -32.36 | -12.31 | -6.56 | |
| Selling, General & Admin | 19.3 | 20.22 | 18.82 | 12.88 | 7.28 | 1.35 | |
| Operating Expenses | 19.3 | 20.22 | 18.82 | 12.88 | 7.28 | 1.35 | |
| Operating Income | -138.23 | -114.02 | -61.14 | -45.24 | -19.58 | -7.91 | |
| Interest Expense | -4.17 | -4.07 | -0.58 | - | - | - | |
| Interest & Investment Income | 9.12 | 14.32 | 10.79 | 2.39 | 0.24 | 0 | |
| Other Non Operating Income (Expenses) | -0.06 | 1.44 | -1.44 | -0.01 | -81.11 | 0.59 | |
| EBT Excluding Unusual Items | -133.35 | -102.33 | -52.37 | -42.86 | -100.45 | -7.33 | |
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.16 | - | |
| Pretax Income | -133.35 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | |
| Net Income | -133.35 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | |
| Net Income to Common | -133.35 | -102.33 | -52.37 | -42.86 | -100.61 | -7.33 | |
| Shares Outstanding (Basic) | 60 | 60 | 49 | 41 | 20 | 0 | |
| Shares Outstanding (Diluted) | 60 | 60 | 49 | 41 | 20 | 0 | |
| Shares Change (YoY) | 1.58% | 23.46% | 19.72% | 102.43% | 4685.59% | -2.73% | |
| EPS (Basic) | -2.21 | -1.71 | -1.08 | -1.06 | -5.02 | -17.48 | |
| EPS (Diluted) | -2.21 | -1.71 | -1.08 | -1.06 | -5.02 | -17.48 | |
| Free Cash Flow | -123.75 | -86.23 | -43.09 | -35.31 | -18 | -7.45 | |
| Free Cash Flow Per Share | -2.05 | -1.44 | -0.89 | -0.87 | -0.90 | -17.77 | |
| Operating Margin | - | - | - | - | - | -550.98% | |
| Profit Margin | - | - | - | - | - | -510.10% | |
| Free Cash Flow Margin | - | - | - | - | - | -518.80% | |
| EBITDA | -138.17 | -113.95 | -61.08 | -45.21 | -19.58 | - | |
| D&A For EBITDA | 0.06 | 0.06 | 0.06 | 0.03 | 0 | - | |
| EBIT | -138.23 | -114.02 | -61.14 | -45.24 | -19.58 | -7.91 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.